Real-world hematocrit control, burden of phlebotomy, and quality of life in patients with polycythemia vera treated with phlebotomy in the United States: results from a real-world survey

BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Therapeutic phlebotomy is widely used in PV care, aimed to lower hematocrit levels to <45%. This study aimed to assess the real-world burden of phlebotomy and patient quality of life (QoL). RESEARCH DESIGN AND METHODS: Data were drawn from the Adelphi Real World PV Disease Specific Programme™, a cross-sectional survey with retrospective data collection, in patients with PV and their treating physicians in the U.S. between August 2025 and February 2026. RESULTS: Thirty-nine physicians reported data for 160 patients; 97 had received a phlebotomy in the 12 months prior to the survey (23 frequent phlebotomy; 74 infrequent phlebotomy). Most (91.5%) had uncontrolled hematocrit levels, defined as ≥1 test ≥45%, and no significant association was found between hematocrit control and phlebotomy frequency. Fatigue was commonly reported as a phlebotomy side effect (69.1%) and as a symptom (19.6%), and the median PROMIS Fatigue score was 56.6 (48.1, 61.1). Median activity impairment on the WPAI was 30.0% (20.0, 65.0). CONCLUSIONS: Current treatments, including phlebotomy (with or without cytoreductive therapy), may not adequately control hematocrit or symptoms, and impair QoL. This highlights a need for treatment strategies that offer control over hematocrit and symptoms while improving QoL.

Authors

Institutions

Publication Details

Journal
Expert Review of Hematology
Published
2026-11-18
DOI
https://doi.org/10.1080/17474086.2026.2764545
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world hematocrit control, burden of phlebotomy, and quality of life in patients with polycythemia vera treated with phlebotomy in the United States: results from a real-world survey

Kristen Marie Pettit, Katie Lewis, Alicia Cerretani, Amber Simpson et al.
3 links
Expert Review of Hematology
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Real-world hematocrit control, burden of phlebotomy, and quality of life in patients with polycythemia vera treated with phlebotomy in the United States: results from a real-world survey

Kristen Marie Pettit, Katie Lewis, Alicia Cerretani, Amber Simpson, Angela Qi Fan, Luis Hernandez, Chloe Hall
article en

Abstract

BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Therapeutic phlebotomy is widely used in PV care, aimed to lower hematocrit levels to <45%. This study aimed to assess the real-world burden of phlebotomy and patient quality of life (QoL). RESEARCH DESIGN AND METHODS: Data were drawn from the Adelphi Real World PV Disease Specific Programme™, a cross-sectional survey with retrospective data collection, in patients with PV and their treating physicians in the U.S. between August 2025 and February 2026. RESULTS: Thirty-nine physicians reported data for 160 patients; 97 had received a phlebotomy in the 12 months prior to the survey (23 frequent phlebotomy; 74 infrequent phlebotomy). Most (91.5%) had uncontrolled hematocrit levels, defined as ≥1 test ≥45%, and no significant association was found between hematocrit control and phlebotomy frequency. Fatigue was commonly reported as a phlebotomy side effect (69.1%) and as a symptom (19.6%), and the median PROMIS Fatigue score was 56.6 (48.1, 61.1). Median activity impairment on the WPAI was 30.0% (20.0, 65.0). CONCLUSIONS: Current treatments, including phlebotomy (with or without cytoreductive therapy), may not adequately control hematocrit or symptoms, and impair QoL. This highlights a need for treatment strategies that offer control over hematocrit and symptoms while improving QoL.

Expert Review of Hematology
University of Michigan (US), Adelphi Group (United Kingdom) (GB), Takeda (United States) (US), Takeda (Japan) (JP)
American Society of Clinical Oncology
Good health and well-being
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon